With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
With more and more biosimilars reaching market, there are considerations around whether to keep patients on their current biosimilar or switch them to another biosimilar as the market dictates, said Paul Forsberg, PharmD, director of pharmacy, Minnesota Oncology.
Transcript
Does Minnesota Oncology have experience switching patients between biosimilars, not just between the reference product and a biosimilar?
We initially launched with biosimilars, and the initial change was going from a reference product over to a biosimilar. At that time, we had conversations, and we created a strategy on, do we do new patients only or do we do just new patients and convert existing patients from reference product over to biosimilars?
Now that we're into the biosimilar journey about 2 years, we're having those same conversations about, do we maintain patients on that existing biosimilar or as the market dictates whether it be from a payer standpoint, whether it's from an internal P&T [pharmacy and therapeutics committee] standpoint, we want to pivot between biosimilar products or supply changes with the biosimilars, are we able to move from biosimilar to biosimilar?
We have had success moving patients from one biosimilar to another biosimilar product, but that's going to be part of that continual biosimilar journey as we evaluate the landscape and determine what's going to be the best outcomes for our patient, not only from a quality and safety standpoint. As we've seen biosimilars launch, we're seeing patients save a significant amount in out-of-pocket expenses associated with their care, and we want to make sure we maintain that with their treatments.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More